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Abstract:   RhoBTB   proteins   constitute   a   subfamily   of   atypical   Rho   GTPases   represented   in  
mammals  by  RhoBTB1,  RhoBTB2,  and  RhoBTB3.  Their  characteristic  feature  is  a  carboxyl  terminal  
extension   that   harbors   two   BTB   domains   capable   of   assembling   cullin   3-­‐‑dependent   ubiquitin  
ligase  complexes.  The  expression  of  all  three  RHOBTB  genes  has  been  found  reduced  or  abolished  
in   a   variety   of   tumors.   They   are   considered   tumor   suppressor   genes   and   recent   studies   have  
strengthened  their  implication  in  tumorigenesis  through  regulation  of  the  cell  cycle  and  apoptosis.  
RhoBTB3   is   also   involved   in   retrograde   transport   from   endosomes   to   the  Golgi   apparatus.  One  
aspect  that  makes  RhoBTB  proteins  atypical  among  the  Rho  GTPases  is  their  proposed  mechanism  
of  activation.  No  specific  guanine  nucleotide  exchange   factors  or  GTPase  activating  proteins  are  
known.   Instead,  RhoBTB  might  be  activated   through   interaction  with  other  proteins   that   relieve  
their  auto-­‐‑inhibited  conformation  and  inactivated  through  auto-­‐‑ubiquitination  and  destruction  in  
the  proteasome.  In  this  review  we  discuss  our  current  knowledge  on  the  molecular  mechanisms  of  
action  of  RhoBTB  proteins  and  the  implications  for  tumorigenesis  and  other  pathologic  conditions.  
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1.  Introduction  
Ras  superfamily  small  guanosine  triphosphatases  (GTPases)  are  important  molecular  switches  
that  regulate  a  myriad  of  signaling  pathways   in  eukaryotes.  They  characteristically  cycle  between  
an   active   GTP-­‐‑bound   state   and   an   inactive   GDP-­‐‑bound   state.   Activation   enables   the   GTPase   to  
interact  with  a  multitude  of  effectors  that  relay  upstream  signals  to  other  cellular  components.  The  
members  of  the  Ras  superfamily  can  be  distributed  into  several  families,  mainly  Ras,  Rho,  Rab,  Arf,  
Ran,  and  Miro,  based  on  sequence  similarities,  each  family  regulating  a  major  cellular  process  [1].  
Within   the   Ras   superfamily   Rho   GTPases   are   key   regulators   of   the   actin   filament   system   and,  
consequently,  of  all  processes  that  depend  on  the  reorganization  of  the  actin  cytoskeleton,  such  as  
membrane  trafficking,  cell  motility,  cytokinesis,  adhesion,  and  morphogenesis.  They  have  also  been  
found   implicated   in  numerous  processes  not  directly   linked   to  actin   reorganization,   like  NADPH  
oxidase   activation,   microtubule   organization,   gene   expression,   cell   cycle   progression,   apoptosis,  
and  tumorigenesis  [2,3].  The  GTPase  cycle  of  Rho  proteins  is  characteristically  modulated  by  three  
major   classes   of   proteins   that   are   targets   of   upstream   signaling   pathways:   guanine   nucleotide  
exchange   factors   (GEFs)   catalyze   the   exchange   of   GDP   for   GTP   to   activate   the   switch;   GTPase  
activating   proteins   (GAPs)   stimulate   the   (typically   low)   intrinsic   GTPase   activity   and,   thus,  
inactivate   the   switch;   guanine   nucleotide-­‐‑dissociation   inhibitors   (GDIs)   play   complex   roles  
stabilizing  the  GTPase  and  regulating  exchange  between  membranes  and  cytosol.  
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Rho   GTPases   are   ubiquitously   expressed   across   the   eukaryotes,   frequently   as   multiple  
paralogs.   In  humans,   the   family   comprises  21  members   that  have  been  grouped   into   subfamilies:  
Cdc42-­‐‑like   (Cdc42,   TC10/RhoQ,   TCL/RhoJ,   Chp/Wrch-­‐‑2/RhoV,   Wrch-­‐‑1/RhoU),   Rac-­‐‑like   (Rac1–3,  
RhoG),  Rho-­‐‑like  (RhoA–C),  Rnd  (Rnd1–2,  Rnd3/RhoE),  RhoD  (RhoD  and  Rif/RhoF),  RhoH/TTF,  and  
RhoBTB   (RhoBTB1–3)   [4].   The   RhoBTB   subfamily   stands   out   for   three   reasons   that   make   these  
proteins   truly   atypical  Rho  GTPases.   First,  RhoBTB  proteins   have   a  peculiar  domain   architecture  
with  a   long  extension  following  the  GTPase  domain.  Second,  their  cellular  roles  bear  no  apparent  
relationship   to   direct   remodeling   of   the   cytoskeleton.   Third,   regulation   of   their   activity  may   not  
involve  specific  GEFs  and  GAPs  but  interaction  with  other  proteins  that  relieve  their  auto-­‐‑inhibited  
conformation   followed   by   auto-­‐‑ubiquitination   and   destruction   in   the   proteasome   instead.   The  
RhoBTB  subfamily  was   identified  during  the  study  of   the  genes  encoding  Rho-­‐‑related  proteins   in  
the   lower   eukaryote  Dictyostelium   discoideum   [5].   Interest   in   RhoBTB   arose  when  RHOBTB2   (also  
called  DBC2,  deleted  in  breast  cancer  2),  was  identified  as  the  gene  homozygously  deleted  in  breast  
cancer   samples   and  was  proposed  as   a   candidate   tumor   suppressor  gene   [6].   Subsequent   studies  
have   strengthened   the   implication   of   RhoBTB   proteins   in   tumorigenesis   and   other   cellular  
processes.  In  this  review  we  shall  present  and  discuss  our  current  knowledge  about  the  emerging  
functions   of   human   RhoBTB   proteins   and   their   associated   molecular   mechanisms,   with   the  
occasional  reference  to  studies  carried  out  in  mouse  models.  
2.  RhoBTB  Architecture  and  Gene  Expression  
The  RhoBTB  subfamily  comprises  three  members:  RhoBTB1  (696  amino  acids),  RhoBTB2  (727  
amino   acids),   and   RhoBTB3   (611   amino   acids).   RhoBTB1   and   RhoBTB2   are   very   similar   to   each  
other   (79%),   whereas   RhoBTB3   is   the   most   divergent   member   (42%   similarity   to   RhoBTB1   and  
RhoBTB2).  RhoBTB  proteins  stand  out  among  all  other  small  GTPases  for  their  domain  architecture:  
the   GTPase   domain   is   followed   by   a   proline-­‐‑rich   region,   a   tandem   of   two   BTB   (broad   complex,  
tramtrack,   and   bric-­‐‑a-­‐‑brac)   domains   and   a   carboxyl   terminal   BACK   (BTB   and   C-­‐‑terminal   Kelch)  
domain  (Figure  1a).  A  detailed  analysis  of  the  domain  architecture  of  RhoBTB  has  been  discussed  in  
a  previous  review  [7].  Here  we  shall  present  a  summary  of  the  key  features  that  incorporates  some  
novel  aspects.  
The  GTPase  domain  of  RhoBTB1  and  RhoBTB2   is  Rho-­‐‑related,   but   contains   some  deviations  
from   the  GTPase   consensus   of  most   Rho  GTPases.   These   include   a   longer   than   usual   Rho   insert  
region,   two   insertions   placed   one   immediately   before   (six   residues)   and   one   after   (10   residues)  
switch   I,   and   a   deletion   (two   residues)   that   affects   the   phosphate/magnesium   binding   region   3  
within   switch   II.   In   addition   the  glycine   residue  equivalent   to  G12   in  Ras  appears   substituted  by  
asparagine.   These   deviations   do   not   prevent   binding   of   GTP,   as   has   been   shown   recently   for  
RhoBTB2,  and  RhoBTB1  is  likely  to  behave  in  the  same  way  [8].  By  contrast,  the  GTPase  domain  of  
RhoBTB3   is   considerably   divergent   and   binds   and   hydrolyzes   ATP   instead   of   GTP   by   virtue   of  
some  critical  amino  acid  replacements  in  the  G4  and  G5  motifs  [9].  RhoBTB3  branches  outside  the  
Rho  family  when  phylogenetic  analysis  takes  into  consideration  the  GTPase  domain  only.  However  
analyses  of  a  large  sample  of  RhoBTB  proteins  from  a  wide  spectrum  of  species  provide  compelling  
phylogenetic  evidence  for  grouping  this  protein  within  the  RhoBTB  subfamily  [10].  The  proline-­‐‑rich  
region   links   the  GTPase   to   the   first  BTB  domain  and   is  a  potential  SH3  domain-­‐‑binding  site.  BTB  
domains   participate   in   homomeric   and   heteromeric   associations   with   other   BTB   domains   and  
function  as  components  of  multimeric  cullin  3-­‐‑dependent  ubiquitin  ligase  complexes.  The  first  BTB  
domain  of  RhoBTB   is  bipartite,   carrying  an   insertion  of  unknown   function.  This  domain  binds   to  
cullin   3   and   to   the   GTPase   domain.   The   BTB   domains   of   RhoBTB   allow   the   formation   of  
homodimers  and  of  heterodimers  with  other  proteins  of  the  RhoBTB  subfamily  [11].  The  carboxyl  
terminal   region   exhibits   similarity   to   a   particular  motif   (the   3-­‐‑box)   of   the   BACK   domain  mainly  
found  in  BTB  proteins  with  kelch  domains  and  probably  involved  in  substrate  orientation  in  cullin  
3-­‐‑based  ubiquitin  ligase  complexes  [12].  Only  RhoBTB3  bears  an  isoprenylation  CAAX  motif  that  is  
typical   for   classical   Rho   GTPases   and   contributes   to,   but   is   not   the   only   determinant   for   the  
localization  of  the  protein  to  membranes  of  the  Golgi  apparatus  [11,13].  
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Figure   1.  Architecture   of   RhoBTB   proteins   and   proposed   mechanism   of   regulation.   (a)   Domain  
structure  of  RhoBTB  proteins.  The  GTPase  domain  is  followed  by  a  proline-­‐‑rich  region,  a  tandem  of  
two   BTB   (broad   complex,   tramtrack,   and   bric-­‐‑a-­‐‑brac)   domains   (the   first   one   is   bipartite)   and   a  
carboxyl  terminal  BACK  (BTB  and  C-­‐‑terminal  Kelch)  domain.  The  cartoon  is  drawn  roughly  to  scale  
and  fits  RhoBTB1  and  RhoBTB2.  RhoBTB3  has  a  shorter  insert  in  the  first  BTB  domain  and  it  bears  
an  isoprenylation  (CAAX)  motif  at  the  end;  and  (b)  a  model  depicting  the  hypothetical  mechanism  
of  activation  and  inactivation  of  RhoBTB.  An  intramolecular  interaction  of  the  GTPase  domain  with  
the   first   BTB   domain   maintains   the   molecule   inactive.   Interaction   with   specific   ligands   would  
provoke  a  conformational  change  that  disrupts  the  intramolecular  interaction.  There  is  probably  not  
a  unique  ligand  binding  site  that  causes  activation  of  RhoBTB  (two  have  been  depicted  in  this  model  
as  examples).  The  GTPase  domain  would   then  be  able   to  bind  and  hydrolyze  GTP   (in   the  case  of  
RhoBTB2  and  probably  also  RhoBTB1)  or  ATP  (in  the  case  of  RhoBTB3)  and  the  first  BTB  domain  
would  be  free  to  assemble  a  cullin  3-­‐‑dependent  ubiquitin  ligase  complex  that  would  tag  the  ligands,  
as  well   as   RhoBTB   itself,   for   degradation   in   the   proteasome.   It   has   not   been   established  whether  
nucleotide  binding  and  cullin  3  binding  are  always  linked.  
The  expression  patterns  of  all  three  RhoBTB  encoding  genes,  both  in  human  and  mouse,  have  
been   discussed   in   a   previous   review   [7].   Briefly,   all   three   genes   are   ubiquitously   expressed,  
although  each  with  a  specific  organ  pattern.  Expression  of  RHOBTB2   is  generally  weaker  than  the  
other  two.  All  three  genes  are  expressed  in  fetal  tissues.  Expression  of  the  mouse  Rhobtb3  gene  has  
been  investigated  in  great  detail  at  tissue  rather  than  whole  organ  level  in  a  gene  trap  mouse  strain  
that   expresses   a   β-­‐‑galactosidase   reporter   under   the   control   of   the   endogenous  Rhobtb3   promoter.  
Expression  of   this  gene   is  nearly  ubiquitous   in   the  embryo,  with  particularly  high   levels   in  bone,  
cartilage,  all  types  of  muscle,  testis,  and  restricted  areas  of  the  nervous  system.  In  the  adult  mous,e  
expression  declines  considerably,  but  persists  at   low  levels   in  cardiac  muscle,   the   tunica  media  of  
blood  vessels,  the  muscularis  of  hollow  organs  and  cartilage,  and  at  high  levels  in  the  seminiferous  
tubules   and   peripheral   nerves   [14].   Expression   levels   of   RHOBTB   genes   change   during   the   cell  
cycle,  in  tumors  and  in  other  circumstances  that  are  described  in  following  sections.  
In  what   follows  we   shall   discuss   the   roles   of   RhoBTB   proteins   in   proteasomal   degradation,  
tumorigenesis  and  vesicle  trafficking,  summarily  presented  in  Figure  2,  and  shall  introduce  several  
interacting  partners  listed  in  Table  1.  
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Figure  2.  Schematic  illustrating  the  roles  of  RhoBTB  proteins  in  tumorigenesis  and  other  processes.  
Proposed  mechanisms   for   (a)   RhoBTB2   and   (b)   RhoBTB3   are   shown.   RhoBTB1   (not   depicted)   is  
likely   to   function   similarly   to   RhoBTB2   but   has   not   been   investigated   extensively.   Blue   arrows  
indicate   factors   that   affect   the   expression   of   the   RhoBTB-­‐‑encoding   gene.   Green   arrows   indicate  
positive  or  stimulatory  links.  Red  arrows  indicate  inhibitory  links.  Interacting  cullins  are  indicated  
with   black   arrows.   The   arrows   do   not   implicate   direct   interactions;   see   Table   1   for   details   on  
interactions.  Recognized  substrates  of  RhoBTB3-­‐‑dependent  ubiquitin  ligase  complexes  are  shown  in  
blue.  Multiprotein  complexes  are  boxed.  
Table   1.   Interaction   partners   of   RhoBTB   and   their   functions.   The   technique   used   to   identify   the  
interaction   is   given   in   brackets.   B2H,   bacterial   two   hybrid;   CL,   chemical   crosslinking;   IP:  
immunoprecipitation;   IVEC,   in   vitro   expression   cloning   followed   by   GST   pull-­‐‑down;   Y2H,   yeast  
two-­‐‑hybrid.  Note  that  some  interactions   included  in  the  table,  particularly  those  found  using  only  
immunoprecipitation,   are   not   necessarily   direct   interactions.   The  
RhoBTB3/LIMD1-­‐‑PHD2-­‐‑VHL-­‐‑HIFα   complex   and   the   RhoBTB2/Hsp90   complex   have   not   been  
investigated  in  detail  in  terms  of  direct  interactions.  Hsp90  is  part  of  the  above  RhoBTB3  complex,  
but   through  PHD2,  not  directly.  Hsp90  chaperone  refers   to  Hsp90  and  co-­‐‑chaperone  components.  
Note  also  that  RhoBTB  proteins  are  capable  of  homo  and  heterodimerization.  
Protein   RhoBTB   Function   Reference  
Cullin  3   1,  2,  3  (Y2H,  IP)   E3  ubiquitin  ligase  component   [8,11,15]  
Cullin  5   2,  3  (Y2H)   E3  ubiquitin  ligase  component   [11]  
Cyclin  E1,  cyclin  B1   3  (IP)   Regulation  of  the  cell  cycle.   [13]  
Hrs   3  (IVEC)   Protein  sorting  for  lysosomal  degradation.   [23]  
5-­‐‑HT7a   3  (Y2H)   Serotonin  receptor.   [18]  
Hsp90  chaperone   2  (IP);  3  (IP)   Protein  folding  and  stabilization.   [8,17]  
LIMD1   3  (IP)   Multifunctional  scaffold  protein.   [17]  
MUF1   1,  2,  (IP);  3  (B2H)   Adaptor  for  cullin  5-­‐‑dependent  ubiquitin  ligase  complexes.   [16]  
PHD2   3  (IP)   Prolyl  hydroxylase.   [17]  
Rab9A,  Rab9B   3  (Y2H)   Retrograde  transport  of  membrane  receptors.   [9]  
TIP47   3  (CL)   Cargo  packaging  for  endosomal  transport.   [9]  
VHL   3  (Y2H,  IP)   Adaptor  for  cullin  2-­‐‑dependent  ubiquitin  ligase  complexes.   [17]  
3.  RhoBTB  and  Proteasomal  Degradation  
The   identification   of   the   BTB   domain   as   adaptor   in   cullin   3-­‐‑dependent   ubiquitin   ligase  
complexes   in   2003   prompted   investigations   into   the   participation   of   RhoBTB   proteins   in   those  
complexes.  We  know  now  that  all  three  RhoBTB  proteins  interact  specifically  with  cullin  3  and  that  
the   interaction   involves   the   first   BTB   domain   and   the   amino   terminal   region   of   cullin   3   [11,15].  
RhoBTB  proteins  may  potentially  interact  with  the  amino  terminal  region  of  cullin  5,  too,  as  shown  
by   a   yeast   two-­‐‑hybrid   approach,   but   this   interaction   is   apparently   not   favored   in   vivo.   Cullin  
3-­‐‑dependent   RhoBTB   complexes   seem   to   incorporate   other   cullins,   as   shown   in  
immunoprecipitation   and   colocalization   studies   [11],   reflecting   the   fact   that   cullins   can  
heterodimerize   and   that   some   RhoBTB-­‐‑interacting   proteins   recruit   themselves   other   cullin  
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complexes.   Such   is   the   case   of  MUF1   (LLRC41,   leucine   rich   repeat   containing   41)   and  VHL   (von  
Hippel-­‐‑Lindau   protein)   discussed   below   (Figure   2b).   RhoBTB   proteins   not   only   target   other  
proteins   for   ubiquitination,   but   they   are,   themselves,   substrates   for   the   cullin   3-­‐‑based   ubiquitin  
ligase  complexes   they   form  [11,15].  Berthold  et  al.  proposed  an  autoregulatory  model   for  RhoBTB  
proteins   that   has   gained   support   in   recent   years   [11].  According   to   this  model,   RhoBTB  proteins  
exist   in   an   inactive   state   through   an   intramolecular   interaction   of   the   first   BTB   domain  with   the  
GTPase  domain.  This  intramolecular  interaction  prevents  binding  to  cullin  3  and  the  formation  of  a  
ubiquitin   ligase   complex.   It   was   proposed   that   the   interaction   with   other   proteins,   including  
potential   substrates,  would   relieve   the  autoinhibitory   conformation  of  RhoBTB3  and   facilitate   the  
binding  to  cullin  3  (Figure  1b).  
Several   potential   substrates   or   activators   of   RhoBTB   have   been   described   in   the   last   years.  
MUF-­‐‑1   is  able   to   interact  with  all   three  RhoBTB  proteins  and   is  degraded   in   the  proteasome  by  a  
RhoBTB3-­‐‑cullin   3-­‐‑dependent   ubiquitin   ligase   complex   [16].   Cyclin   E,   too,   is   targeted   for  
ubiquitination   by   a   RhoBTB3-­‐‑cullin   3-­‐‑dependent   ubiquitin   ligase   complex   [13].   RhoBTB3   also  
participates   in   the   degradation   of   HIFα   (hypoxia   inducible   factor   α)   through   a   multimolecular  
complex  that  involves  VHL  [17].  MUF1,  cyclin  E  and  HIFα  have  implications  in  tumorigenesis  and  
are   discussed   below   in   more   detail.   RhoBTB3   also   interacts   with   the   5-­‐‑HT7a   receptor,   the   most  
common   splice  variant  of   the   serotonin   receptor   7.  This   receptor   is   involved   in   a  wide  variety  of  
pathophysiological   processes   of   the   central   nervous   system.   Interestingly,   the   5-­‐‑HT7a   receptor  
interacts  with   cullin   3   independently   of  RhoBTB3,   and  RhoBTB3   apparently   inhibits   proteasomal  
degradation  of  the  receptor  [18].  
The   autoinhibition   model   outlined   above   has   received   one   more   tweak   in   recent   years.  
Manjarrez   et   al.   identified   RhoBTB2   as   an   interactor   of   the   Hsp90   chaperone   machinery   in   an  
immunoprecipitation   screening   and   showed   that   this  multimolecular   complex   unlocks   RhoBTB2,  
enabling  GTP  binding   [8].   The   interaction   of  RhoBTB2  with   cullin   3   is   also  dependent   on  Hsp90  
activity,   as   it   was   significantly   reduced   in   the   presence   of   the   Hsp90   inhibitor   geldanamycin.  
Further  affinity  purification  studies  with  a  tagged  RhoBTB2  yielded  the  majority  of  components  of  
the  COP9  signalosome,  a  multiprotein  complex  that  binds  to,  and  regulates,  cullin  3  [19].  The  Hsp90  
chaperone  machinery   undergoes   a   complex   ATP-­‐‑driven   reaction   cycle   that   involves   the   binding  
and  detachment  of  various  components  [20].  Using  a  biochemical  approach  with  various  inhibitors  
of   Hsp90  Manjarrez   et   al.   worked   out   a   model   in   which   RhoBTB2   associates   to   an   intermediate  
Hsp90  complex  that  upon  binding  of  ATP  releases  some  components  and  breaks  the  intramolecular  
interaction   of   the   GTPase   domain   of   RhoBTB2   with   the   first   BTB   domain.   This   conformational  
change  enables  binding  of  GTP  and  cullin  3   to   their   respective  domains.  The  Hsp90  chaperone   is  
then  released  from  the  RhoBTB2-­‐‑cullin  3  complex,  allowing  components  of  the  COP9  signalosome  
to  assemble  and  regulate  the  ubiquitin  ligase  complex  [8].  Considering  the  high  degree  of  similarity  
between  RhoBTB2  and  RhoBTB1,  this  mechanism  is  very  likely  to  apply  to  RhoBTB1,  too.  Although  
Hsp90  does  not  seem  to  interact  with  RhoBTB3,  it  is  incorporated  in  a  RhoBTB3-­‐‑dependent  complex  
that   targets  HIFα   through   interaction  with   the  prolyl   hydroxylase  PHD2  and  may  play   a   similar  
stabilizing  role  [17].  
4.  RhoBTB  and  Vesicle  Trafficking  
Although   available   antibodies   fail   to   recognize   any   endogenous   RhoBTB   in   fixed   cells   and  
tissues,   studies   with   ectopically-­‐‑   expressed   epitope-­‐‑tagged   proteins   have   revealed   a   vesicular  
pattern,   frequently   in   the   proximity   of   microtubules   for   RhoBTB2   [11,21]   and   predominantly  
surrounding  the  centrosome  for  RhoBTB3  [9,11].  Most  RhoBTB3  co-­‐‑localizes  with  Golgi  apparatus  
markers  but  some  co-­‐‑localizes  with  early  endosome  markers  or  in  close  vicinity  to  microtubules  or  
stress  fibers  [9,11].  These,  and  other  early  studies,  suggested  a  participation  of  RhoBTB  proteins  in  
vesicle   trafficking  processes   (reviewed   in   [7]).  Compelling   evidence   for   a   role   in   these   processes,  
more   specifically   in   retrograde   transport   from   endosomes   to   the   Golgi   apparatus,   has   been  
provided  for  RhoBTB3.  
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Espinosa   et   al.   identified   RhoBTB3   as   an   interacting   partner   of   activated   Rab9   in   a   yeast  
two-­‐‑hybrid  screen  [9].  The  interaction  is  specific  for  this  Rab  out  of  54  Rabs  tested.  Rab9  is  present  
on   late   endosomes   and   on   transport   vesicles   that   travel   from   late   endosomes   toward   the   Golgi  
complex.  Mannose   6-­‐‑phosphate   receptors   are   recycled   following   this   retrograde   transport   route,  
which   requires   Rab9,   the   cargo   selection   protein   TIP47,   cytoplasmic   dynein,   additional   small  
GTPases,  and  a  SNARE  complex  [22].  RhoBTB3  appears  as  a  component  of  this  retrograde  transport  
complex  and  appears  to  interact  also  with  TIP47  [9].  When  RhoBTB3  is  depleted  by  gene  silencing,  
the  Golgi  apparatus  becomes  fragmented  [13],  the  mannose  6-­‐‑phosphate  receptor  adopts  a  disperse  
localization   in  Rab9  positive  vesicles,   and   the   secretion  of   the   lysosomal   enzyme  hexosaminidase  
increases,  but  endocytosis  and  exocytosis  are  not  changed,  all   indicative  of  a  specific  alteration  of  
retrograde   transport   [9].   Based   on   these   and   additional   experimental   evidence,   the   authors  
proposed  a  model  in  which  Rab9  on  vesicles  travelling  from  late  endosomes  to  the  Golgi  apparatus  
relieves   the   autoinhibitory   conformation   of   RhoBTB3   and   allows   maximal   ATP   hydrolysis.  
Activation  of  RhoBTB3  then  releases  TIP47,  facilitating  vesicle  uncoating  and  membrane  fusion.  
RhoBTB3   also   binds   to   the   ubiquitin-­‐‑interacting   motif   of   Hrs   (hepatocyte   growth  
factor-­‐‑regulated   tyrosine   kinase   substrate),   an   early   endosome   protein   that   controls  
endosome-­‐‑to-­‐‑lysosome   trafficking   and   may,   therefore,   participate   in   sorting   of   membrane   cargo  
proteins   to   multivesicular   bodies   for   subsequent   degradation   in   the   lysosome,   an   aspect   of   the  
RhoBTB3  physiology  that  requires  further  investigation  [23].  
5.  RhoBTBs  as  Tumor  Suppressors  
Consistent  with   roles   as   tumor   suppressors,   expression  of   all   three  RHOBTB   genes  has  been  
found   reduced   or   extinguished   in   a   variety   of   tumor   types.   Expression   of   RHOBTB2,   the   first  
member   of   the   family   to   be   proposed   as   a   candidate   tumor   suppressor   gene,   has   been   found  
decreased  in  breast  [6,24,25],  lung  [26],  bladder  [27,28],  and  stomach  [29]  cancers,  in  osteosarcomas  
[30],   as  well   as   in   cell   lines  derived   from  breast,   lung   [6],   and  bladder   [27]   tumors,   and  HNSCCs  
(head  and  neck  squamous  cell  carcinomas)  [31].  Very  often  the  degree  of  expression  correlates  with  
the  primary  location,  grading,  staging,  or  other  features  of  the  tumor.  Expression  of  RHOBTB1  has  
been  found  decreased  in  kidney,  breast  and  stomach  tumors  in  a  cancer  profiling  array  [11],  as  well  
as   in   HNSCCs   [32]   and   in   colon   cancer   tissues   [33].   Expression   of   RHOBTB3   has   been   found  
moderately  but  significantly  decreased  in  breast,  kidney,  uterus,  lung,  and  ovary  tumor  samples  in  
a  cancer  profiling  array  [11]  and  in  various  subtypes  of  renal  cell  carcinomas  [17].  Interestingly,  the  
expression  changes  of  RHOBTB1  and  RHOBTB3  correlated  with  those  of  CUL3  (the  gene  encoding  
cullin  3)  in  the  same  samples.  
Decreased  RHOBTB  mRNA  levels  are  rarely  caused  by  mutations.  The  reported  rare  mutations  
and   other   genetic   alterations   have   been   described   in   detail   in   a   previous   review   [7].   Epigenetic  
alterations,  more  specifically  promoter  methylation,  is  one  potential  mechanism  to  account  for  the  
reduced  expression  of  these  genes  in  tumors.  The  promoter  regions  of  all  three  RHOBTB  genes  have  
a   high   GC   content   with   CpG   islands.   The   hypermethylation   of   CpG   islands   results   in   the  
downregulation  or  complete  abrogation  of  gene  expression  and  is  a  frequent  epigenetic  alteration  in  
primary   tumors   [34].   RHOBTB2   promoter   methylation,   normally   a   rare   event,   has   been   found  
increased   and   correlated   to   reduced   or   abolished   expression   of   the   gene   in   breast   [25,35,36]   and  
bladder   [28]   cancers.  RHOBTB2   promoter  methylation   appears   to   associate  with  more   advanced  
tumor  stages  [25]  or  a  particular  status,  like  the  presence  of  p53  mutation,  HER2-­‐‑positive  status  [25],  
or  progesterone  receptor  negative  status  [36].  In  fact,  methylation  of  RHOBTB2  and  other  genes  in  
peripheral  blood  is  a  potential  epigenetic  marker  for  predicting  the  risk  of  breast  cancer  development  
[37].  
A  different  mechanism  of  downregulation  is  provided  by  the  action  of  microRNAs,  a  family  of  
regulatory   RNAs  whose   expression   levels   are   altered   in  many   types   of   cancer   [38].   Two   studies  
have   identified  RHOBTB1   as   a   target   of   the   microRNA  miR-­‐‑31.   In   one   study   overexpression   of  
miR-­‐‑31   in   esophagus   caused   by   zinc   deficiency,   a   risk   factor   for   the   development   of   esophageal  
squamous  cell   carcinoma,  was   found  associated   to  down-­‐‑regulation  of  RHOBTB1   [39].   In  another  
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study  it  was  found  that  silencing  of  RHOBTB1  in  the  colon  cancer  cell  line  HT29  mimics  the  effects  
of   increased  miR-­‐‑31  expression,  namely   increase  of   cell  proliferation  and  promotion  of   cell   clonal  
growth,   suggesting   that   downregulation   of   RHOBTB1   is   responsible   for   the   tumor-­‐‑promoting  
effects  of  miR-­‐‑31  [33].  
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6.  Tumorigenic  Mechanisms  of  RhoBTB  
6.1.  Regulation  of  the  Cell  Cycle  
Mounting   evidence   is   beginning   to   shed   light   into   the  molecular  mechanisms   of   the   tumor  
suppressor  activity  of  RhoBTB  proteins.  Although  many  aspects  remain  speculative,  regulation  of  
the  cell  cycle  is  an  emerging  common  theme  that  is  gaining  wider  support.  The  effects  of  RhoBTB2  
on   cell   proliferation   were   observed   in   early   studies   where   overexpression   of   the   protein   in   the  
breast  cancer  cell  line  T-­‐‑47D  (a  cell  line  that  lacks  RHOBTB2  transcripts)  effectively  suppressed  cell  
growth   and   increased   the   apoptotic   ratio   in   vitro   [6,40].   Similarly,   overexpression   of   RhoBTB2   in  
osteosarcoma  cells  significantly  arrested  cells  at  G1  and  resulted  in  apoptosis  [30].  More  puzzling  is  
a  recent  report  showing  that  in  the  thyroid  carcinoma  cell  line  SW579  treatment  with  recombinant  
RhoBTB2  for  24  h   inhibited  proliferation  and  provoked  an   increase  of   the  apoptotic  ratio   through  
the  mitochondrial  apoptotic  signaling  pathway  [41].  This  report  provides  no  explanation  as  to  how  
the   exogenously   added   RhoBTB2   exerts   those   actions.   The   growth   arrest   effect   of   RhoBTB2   on  
T-­‐‑47D  cells  has  been  explained  by  the  downregulation  of  cyclin  D1.  Cyclin  D1  is  upstream  of  cyclin  
E  and   the  overexpression  of  any  of  both  prevented   the  growth  arrest  effect  of  RhoBTB2   [42].  The  
effect   on   cyclin  D1   is   only   partially   dependent   on   proteasomal   degradation   [43].   It   has   not   been  
investigated  whether  cyclin  D1  or  any  other  cyclin  is  targeted  by  RhoBTB2  for  ubiquitination.  
Further  in  support  for  roles  of  RhoBTB2  in  cell  cycle  regulation,  RHOBTB2  has  been  identified  
as  a  target  of  the  E2F1  transcription  factor  [44].  RhoBTB2  levels  increase  upon  initiation  of  prophase  
and  decrease   at   telophase,   and   this   effect  depends  on  E2F1.  RhoBTB2   levels   also   increase  during  
drug-­‐‑induced  apoptosis  in  an  E2F1-­‐‑dependent  manner.  Consequently,  long-­‐‑term  overexpression  of  
RHOBTB2  had  a  negative  effect  on  cell  cycle  progression  and  proliferation,  and  the  downregulation  
of  RHOBTB2  delayed  the  onset  of  apoptosis.  Of  note,  RHOBTB2  has  also  been   identified  as  a  p53  
candidate  target  gene,  but  the  implications  have  not  been  investigated  [45].  Although  there  are  no  
studies  addressing  RhoBTB1  specifically,  much  of  what  we  know  about  RhoBTB2  is  likely  to  apply  
to  RhoBTB1  because  of  their  similarity.  
A  clear  link  between  RhoBTB  and  the  regulation  of  the  cell  cycle  has  been  described  in  a  recent  
study   from   the  Pfeffer   lab   [13].   The   observation   that  depletion  of  RhoBTB3   caused   increased   cell  
size  and  signs  of  genomic  instability  prompted  these  investigators  to  explore  possible  alterations  of  
the   cell   cycle.   It  was   observed   that   depletion   of   RhoBTB3   causes   S-­‐‑phase   arrest   in   cultured   cells  
accompanied  by  increased  levels  of  cyclin  E  and  increased  activity  of   its  dependent  kinase  CDK2.  
Cyclin  E  regulates  the  cell  cycle  transition  from  G1  to  S  phase  and  is  degraded  before  entry  into  G2  
phase   by   two   independent   cullin-­‐‑mediated   pathways,   a   cullin   1-­‐‑dependent   SCF-­‐‑FBW7   pathway  
that   targets   phosphorylated   cyclin   E,   and   a   less-­‐‑well   characterized   cullin   3   pathway   that   targets  
free,  unphosphorylated  cyclin  E  [46].  RhoBTB3  binds  cyclin  E1  (and  to  a  lesser  extent  cyclin  B1)  and  
this  interaction  is  not  coupled  to  binding  of  the  cyclin  to  CDK2.  RhoBTB3  then  targets  cyclin  E  for  
ubiquitination  by  a  cullin  3-­‐‑dependent  ubiquitin  ligase  complex  that  resides  at  the  Golgi  apparatus.  
Similar   to  RhoBTB2,  RhoBTB3  protein   levels   fluctuate   along   the   cell   cycle,  with   an   accumulation  
during  the  S  phase  after  the  plateau  of  cyclin  E  [13].  Deregulation  of  cyclin  E  levels  is  common  in  
tumor  cells  and  can  have  a  significant  impact  on  cell  proliferation,  as  shown  in  breast  cancers  where  
high  cyclin  E  correlates  consistently  with  poor  prognosis  [47].  
6.2.  Modulation  of  the  Adaptive  Response  to  Hypoxia  
Zhang   et   al.   have,   very   recently,   described   a   novel   function   and   potential   tumorigenic  
mechanism  for  RhoBTB3.  The  authors  of  this  study  identified  RhoBTB3  as  an  interacting  partner  for  
VHL   in   a   yeast   two-­‐‑hybrid   screen   [17].  VHL   is   a   tumor   suppressor   that   normally   functions   as   a  
component   of   a   cullin   2-­‐‑dependent  ubiquitin   ligase   complex   that   targets  hydroxylated  HIF.  HIFs  
are  key   regulators  of   adaptive   responses   to   low  oxygen   concentration.   In   the  presence  of   oxygen  
their   α-­‐‑subunits   are   rapidly   degraded   after   hydroxylation   by   the   prolyl   oxidase   PHD2.   Under  
hypoxia  conditions  HIFs  accumulate  and  bind  to  hypoxia  responsive  elements  of  various  genes,  in  
many  cases  related  to  aspects  of  cancer  growth.  In  fact,  aberrant  accumulation  or  activation  of  HIFs  
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is   closely   linked   to  many   types   of   cancer   [48].   RhoBTB3   acts   as   a   scaffold   for   a  multicomponent  
complex   that   contains   PHD2   and   VHL   and   facilitates   ubiquitination   of   HIFα.   Additionally  
RhoBTB3   appears   to   heterodimerize   with   LIMD1,   an   adaptor   for   PHD2   and   VHL,   and   this  
interaction   enhances   the   activity   of   the   complex.   The   chaperone   Hsp90   is   incorporated   to   the  
complex   through   interaction  with   PHD2   and   although   it   does   not   seem   to   interact   directly  with  
RhoBTB3,   it  may   contribute   to   relieve   its   autoinhibitory   conformation,   as   proposed   for  RhoBTB2  
and   discussed   above   [8].   Hypoxia   apparently   reduces   the   formation   of   the   RhoBTB3-­‐‑dependent  
multicomponent  complex,  resulting  in  an  accumulation  of  HIFα.  
Evidence   that   RhoBTB3   functions   as   a   tumor   suppressor   has   been   provided   in   xenograft  
experiments  with  Ras-­‐‑transformed  embryonic   fibroblasts   isolated   from  Rhobtb3  deficient  mice  or  
HeLa   cells   in  which  RHOBTB3  was   silenced.   The   xenografts   derived   from  RhoBTB3   deficient   or  
silenced   cells   were   larger   and   had   increased   levels   of   HIFα   and   their   gene   targets   compared   to  
those   from   control   cells   [17].   The   authors   proposed   that   RhoBTB3   inhibits   tumorigenesis   by  
maintaining   low  HIFα   levels   and   consequently   suppressing   the  Warburg   effect,   a   shift   towards  
high  rate  of  glycolysis  and  lactic  acid  fermentation  that  characterizes  most  cancer  cells.  
6.3.  Other  Potential  Tumorigenic  Mechanisms  
Further   studies   have   provided   pieces   of   evidence   for   additional   potential   tumorigenic  
mechanisms  of  RhoBTB  proteins,  but  they  are  not  as  well  investigated  as  the  mechanisms  described  
above   for   RhoBTB3.   McKinnon   et   al.   reported   a   decrease   in   the   chemokine   CXCL14   mRNA  
expression  upon  silencing  of  RHOBTB2  in  primary  lung  epithelial  cells.  The  same  effect  was  elicited  
by   silencing  RHOBTB1   or  RHOBTB2   in   keratinocytes,   and   conversely,   expression   of   RhoBTB2   in  
HNSCCs   restored   CXCL14   expression.   These   effects   are   apparently   independent   of   cullin  
3-­‐‑mediated  protein  degradation   [31].  CXCL14   controls  dendritic   cell   infiltration  and  angiogenesis  
and  its  expression  is  frequently  lost  in  diverse  epithelial  tumors,  including  most  HNSCCs  [49].  
Ling  et  al.  reported  that  ectopic  expression  of  RHOBTB2  in  two  human  metastatic  breast  cancer  
cell   lines,   MDA-­‐‑MB-­‐‑231   and   MDA-­‐‑MB-­‐‑435,   inhibits   cell   migration   and   invasiveness   through   a  
mechanism   that   involves   upregulation   of   BRMS1   (breast   cancer   metastasis   suppressor   1)   and  
decreased  phosphorylation  of  ezrin  and  Akt2   [50].  Ezrin   is  a  cytoskeleton  and  signaling  molecule  
that   regulates   cell   adhesion,   migration,   and   invasion,   whereas   Akt2   is   a   kinase   involved   in  
invasiveness  of  breast  cancer  cells  and  is  able  to  phosphorylate  ezrin  [51].  
Finally,   Schenková   et   al,   identified   MUF1   in   a   two-­‐‑hybrid   screening   for   RhoBTB3   binding  
partners  [16].  MUF1  is  a  ubiquitously  expressed  nuclear  protein  and  carries  a  BC-­‐‑box  that  functions  
as   a   linker   in  multicomponent   cullin   5-­‐‑dependent  ubiquitin   ligase   complexes,   followed  by  a  LLR  
region  involved  in  dimerization.  MUF1  co-­‐‑immunoprecipitates  all  three  RhoBTB  proteins  and  may  
be  a  substrate  for  RhoBTB-­‐‑cullin  3  ubiquitin  ligase  complexes  independently  of  its  interaction  with  
cullin   5.   The   function   of   MUF1   is   unknown,   but   it   becomes   phosphorylated   by   ATM   (ataxia  
telangiectasia  mutated)/ATR   (ATM  and  Rad3   related)  upon  DNA  damage  and   is   suspected   to  be  
involved   in   the   DNA   damage   response   [16].   Thus,   MUF1   provides   an   additional   tumorigenic  
mechanism   for   RhoBTB   proteins  worth   exploring   and   together  with   the   RhoBTB3-­‐‑VHL   example  
discussed   above,   one   more   example   of   crosstalk   between   cullin-­‐‑dependent   ubiquitination  
pathways.  
7.  Implications  in  Other  Diseases  and  Animal  Models  of  RhoBTB  Function  
While  evidence  for  participation  of  RhoBTB  proteins  in  vesicle  trafficking  and  tumorigenesis  is  
mounting,   and   the   associated   molecular   mechanisms   are   being   elucidated,   additional   roles   are  
emerging   that   still   require   further   investigations.  Consistent  with   the  pattern  of  expression  of   the  
gene   encoding   RhoBTB3   in   selected   areas   of   the   nervous   system,   roles   for   this   protein   in  
neurological  processes  can  be  anticipated.  Large  scale  transcriptional  studies  suggest  that  RhoBTB3  
might  be   implicated   in   the  development  of  psychotic  disorders  and  Alzheimer’s  disease.  Using  a  
convergent   functional  genomics   approach  Kurian   et   al.   identified  RHOBTB3   as   a   candidate  blood  
biomarker  for  psychotic  disorders.  RHOBTB3  gene  expression  was  found  decreased  in  the  blood  of  
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patients   with   high   hallucination   states   [52].   A   previous   gene   expression   profiling   study   found  
decreased   RHOBTB3   expression   in   the   frontal   cortex   of   schizophrenic   patients   who   completed  
suicide   [53].  RHOBTB3   has  also  been  proposed  as  a   candidate  vulnerability  gene   for  Alzheimer’s  
disease,   vulnerability   being   defined   as   higher   expression   in   the   CA1   versus   CA3   region   of   the  
hippocampus  and  increased  expression  in  disease  [54].  
RhoBTB1   has   emerged   recently   as   a   component   of   a   signaling   mechanism   that   regulates  
vascular  function  and  blood  pressure.  RHOBTB1  has  been  identified  as  a  target  gene  of  the  nuclear  
hormone  receptor  PPARγ  (peroxisome  proliferator-­‐‑activated  receptor  γ)  and  binding  sites  for  this  
receptor   have   been   found   in   the   RHOBTB1   locus   [55].   PPARγ   is   a   well-­‐‑known   regulator   of  
adipogenesis,  but  also  has  antihypertensive  and  vascular  protecting  effects  directly  in  the  vascular  
endothelium   and   smooth   muscle   [56].   RhoBTB1   mRNA   and   protein   levels   are   decreased   in   the  
aorta   of   mice   expressing   a   dominant   negative   PPARγ.   These   mice   also   present   a   concomitant  
decrease   in   cullin   3,   and   it   has   been   proposed   that   RhoBTB1   regulates   cullin   3   levels   or   activity  
which,   in   turn,   regulates  RhoA   turnover   in   smooth  muscle   [55].  RhoA   turnover   is  mediated  by  a  
cullin   3-­‐‑dependent   complex,   but   the   specific   role   of   RhoBTB1   in   this   complex   remains   to   be  
elucidated.  
A   single   case   of   a   male   carrying   a   balanced   paracentric   inversion   of   chromosome   5   that  
disrupts  RHOBTB3   has   been  published.   This   patient   presented   asymmetric   leg   growth   and   large  
hands,  and  behavior  problems.  It  has  not  been  determined  whether  disruption  of  RHOBTB3  is  the  
cause  of  those  alterations  [57].  As  mentioned  above,  a  few  pathogenic  mutations  of  RHOBTB2  have  
been  described  but  they  affect  only  tumors.  No  mutations  have  been  reported  for  RHOBTB1.  
Almost  all   the   information  about   the  roles  of  RhoBTB  proteins  discussed  until  now  has  been  
gained  from  studies  in  vitro  or  in  cells  in  culture.  To  understand  the  function  of  these  proteins  at  the  
whole  organism  level  one  needs  to  resort  to  animal  models.  To  date  only  a  mouse  model  of  Rhobtb3  
disruption  (a  gene  trap  knockout)  has  been  characterized  to  some  extent.  Disruption  of  the  Rhobtb3  
gene   causes   reduced   perinatal   viability,   a   postnatal   growth   defect   that   persists   in   males   after  
weaning   and   reduced   testis   size   [14].   The   reduced   testis   size   is   likely   associated   to   the   marked  
fertility   defect   that   characterizes   Rhobtb3   deficient   males,   but   females   are   also   present   reduced  
fertility  [58].  Standard  tests  performed  by  the  Sanger  Centre,  where  the  mouse  model  was  created,  
revealed  reduced  grip  strength,  suggesting  roles   in  neural  processes  and  consistent  with  localized  
expression   of  Rhobtb3   in   areas   of   the   central   nervous   system   and   in   peripheral   nerves.   Platelets  
isolated   from   Rhobtb3-­‐‑deficient   mice   present   aggregation   and   degranulation   defects,   but   their  
morphology  is  unaffected.  These  defects  may  be  caused  by  subtle  alterations  of  the  granulogenesis  
process   in   the  megakaryocyte,  which   is  dependent   on   correct   functioning  of   the  Golgi   apparatus  
[59].  
Lack   of  RhoBTB3  did  not   affect   the   rate   of   proliferation   of   primary   lung   fibroblasts   isolated  
from   10-­‐‑week-­‐‑old   animals   [14],   but   higher   proliferation   rates   have   been   reported   in   mouse  
embryonic  fibroblasts  [17].  Ablation  of  Rhobtb3  only  caused  very  modest  changes  in  the  pattern  of  
gene  expression  of  adult  heart  and  brain  [14].  Collectively  these  observations  seem  to  indicate  that  
RhoBTB3  plays  more  prominent  roles  at  early  stages  of  development,  consistent  with  the  pattern  of  
expression  of  the  Rhobtb3  gene  in  the  mouse.  
8.  Conclusions  
The  molecular  mechanisms  of  action  of  RhoBTB  proteins  are  beginning  to  be  elucidated  and,  in  
most  cases,  revolve  around  their  role  in  ubiquitination  and  proteasomal  degradation.  As  it  appears,  
RhoBTB  proteins  cannot  be  understood  outside  multiprotein  complexes,  several  examples  of  which  
have   been   uncovered   in   recent   years.   The   evidence   gathered   to   date   also   supports   the  
autoregulatory  model  proposed  in  early  studies  while  suggesting  that  there  is  not  a  unique  pattern  
of   interaction   and   activation   of   RhoBTB   (Figure   1b).   For   example,   MUF1   binds   the   carboxyl  
terminal   region   of   RhoBTB3   downstream   of   the   GTPase   domain   [16],   whereas   cyclin   E   requires  
residues  at   the  amino  and  carboxyl   terminus   [13]  and  Rab9  binds   to   the  carboxyl   terminal   region  
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downstream  of  the  first  BTB  domain  [9].  The  interaction  of  RhoBTB2  with  components  of  the  Hsp90  
chaperone  is  complex  and  requires  the  GTPase  domain  and  motifs  downstream  of  this  domain  [8].  
Some   of   the   tumorigenic   mechanisms   of   RhoBTB   proteins   are   starting   to   take   shape,   in  
particular   the   participation   in   the   regulation   of   the   cell   cycle.   RhoBTB3   appears   to   have   a   dual  
function   at   the   Golgi   apparatus,   regulating   vesicle   trafficking   and   the   S/G2   transition   of   the   cell  
cycle  through  different  sets  of  interactions  [9,13].  It  remains  to  be  established,  at  least  for  RhoBTB3,  
whether  some  of  their  functions  are  independent  of  the  formation  of  cullin  3-­‐‑dependent  ubiquitin  
ligase   complexes.  Notably,   the   studies   outlined   in   this   review  have   revealed   several   instances   of  
crosstalk  between  complexes  dependent  on  various  cullins  (Figure  2b).  
Apart   from  their  unusual  domain  architecture  and  their  roles,  another  aspect  makes  RhoBTB  
proteins   atypical,   namely   their   possible  mechanisms   of   activation   and   inactivation.   There   are   no  
known  GEFs  or  GAPs  for  these  proteins,  but  the  current  evidence  suggests  that  activation  requires  
the  interaction  with  particular  ligands.  Rab9  and  Hsp90  bind  to  the  respective  RhoBTB  and  facilitate  
nucleotide  binding  and  in  the  case  of  Hsp90  assembly  of  a  cullin  3-­‐‑dependent  complex  and  could,  
therefore,  be  considered  activators.  Other  proteins,  like  MUF1  and  cyclin  E  are  possibly  substrates  
that  bind  to  previously  activated  RhoBTB-­‐‑cullin  3  complexes.  A  likely  mechanism  for   inactivation  
of  RhoBTB  proteins  would   involve  auto-­‐‑ubiquitination  by   the  cullin  3-­‐‑dependent  ubiquitin   ligase  
complexes   they   form,   followed   by   proteasomal   degradation   (Figure   1b).   This   is   not   an   unusual  
mechanism,  as  other  Rho  GTPases  are  to  some  extent  modulated  by  proteasomal  degradation  [60].  
Although   considerable   progress   has   been   made   in   recent   years   towards   deciphering   the  
mechanisms   of   action   and   regulation   of   RhoBTB   proteins,   future   work   will   hopefully   help   to  
achieve  a  deeper  understanding  of   the  functioning  of   these  proteins  and  their  participation   in   the  
pathogenesis  of  cancer  and  other  conditions.  
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